Novartis AG EBITDA 2012-2026 | NVS

Novartis AG EBITDA for the quarter ending March 31, 2026 was $5.443B, a 7.08% decline year-over-year.

  • Novartis AG 2025 EBITDA was 22.919B, a 10.94% increase from 2024.
  • Novartis AG 2024 EBITDA was 20.658B, a 13.81% increase from 2023.
  • Novartis AG 2023 EBITDA was 18.152B, a 21.74% increase from 2022.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Novartis AG EBITDA 2012-2026 | NVS

  • Novartis AG 2025 EBITDA was 22.919B, a 10.94% increase from 2024.
  • Novartis AG 2024 EBITDA was 20.658B, a 13.81% increase from 2023.
  • Novartis AG 2023 EBITDA was 18.152B, a 21.74% increase from 2022.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$887.6B
Johnson & Johnson (JNJ)$574.4B
AbbVie (ABBV)$367.7B
Roche Holding AG (RHHBY)$318.8B
Merck (MRK)$299.9B
Novo Nordisk (NVO)$167.5B
Pfizer (PFE)$153.1B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B